Intellia Therapeutics, Inc. announced that the first patient has been dosed with NTLA-5001, the company’s ex vivo CRISPR/Cas9 genome editing candidate for the treatment of AML.
[Intellia Therapeutics, Inc.]
Sorry, but the selected Zotpress account can't be found.